Green Cross Medical Science Corporation (142280) - Total Assets

Latest as of March 2026: ₩91.16 Billion KRW ≈ $61.78 Million USD

Based on the latest financial reports, Green Cross Medical Science Corporation (142280) holds total assets worth ₩91.16 Billion KRW (≈ $61.78 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 142280 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Green Cross Medical Science Corporation - Total Assets Trend (2014–2025)

This chart illustrates how Green Cross Medical Science Corporation's total assets have evolved over time, based on quarterly financial data. Explore Green Cross Medical Science Corporation (142280) investment intensity to see how much of total assets are deployed in long-term investments.

Green Cross Medical Science Corporation - Asset Composition Analysis

Current Asset Composition (December 2025)

Green Cross Medical Science Corporation's total assets of ₩91.16 Billion consist of 45.0% current assets and 55.0% non-current assets.

Asset Category Amount (KRW) % of Total Assets
Cash & Equivalents ₩0.00 0.4%
Accounts Receivable ₩21.06 Billion 23.3%
Inventory ₩17.45 Billion 19.3%
Property, Plant & Equipment ₩0.00 0.0%
Intangible Assets ₩483.93 Million 0.5%
Goodwill ₩253.76 Million 0.3%

Asset Composition Trend (2014–2025)

This chart illustrates how Green Cross Medical Science Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Green Cross Medical Science Corporation market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Green Cross Medical Science Corporation's current assets represent 45.0% of total assets in 2025, a decrease from 76.4% in 2014.
  • Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, down from 0.6% in 2014.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2014.
  • Asset Diversification: The largest asset category is accounts receivable at 23.3% of total assets.

Green Cross Medical Science Corporation Competitors by Total Assets

Key competitors of Green Cross Medical Science Corporation based on total assets are shown below.

Company Country Total Assets
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥14.18 Billion
SIMCERE PHARMAC. GRP LTD
F:S2P
Germany €14.73 Billion
Curaleaf Holdings Inc.
TO:CURA
Canada CA$2.88 Billion
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
China CN¥4.44 Billion
Walvax BioTech
SHE:300142
China CN¥11.13 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion

Green Cross Medical Science Corporation - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.17 1.02 1.41
Quick Ratio 0.68 0.60 0.78
Cash Ratio 0.00 0.00 0.04
Working Capital ₩5.96 Billion ₩1.13 Billion ₩23.85 Billion

Green Cross Medical Science Corporation - Advanced Valuation Insights

This section examines the relationship between Green Cross Medical Science Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 1.67
Latest Market Cap to Assets Ratio 0.00
Asset Growth Rate (YoY) 2.9%
Total Assets ₩90.51 Billion
Market Capitalization $50.61 Million USD

Valuation Analysis

Below Book Valuation: The market values Green Cross Medical Science Corporation's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Green Cross Medical Science Corporation's assets grew by 2.9% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Green Cross Medical Science Corporation (2014–2025)

The table below shows the annual total assets of Green Cross Medical Science Corporation from 2014 to 2025.

Year Total Assets Change
2025-12-31 ₩90.51 Billion
≈ $61.34 Million
+2.88%
2024-12-31 ₩87.97 Billion
≈ $59.62 Million
-2.82%
2023-12-31 ₩90.53 Billion
≈ $61.35 Million
-6.16%
2022-12-31 ₩96.47 Billion
≈ $65.38 Million
+0.88%
2021-12-31 ₩95.63 Billion
≈ $64.81 Million
-9.44%
2020-12-31 ₩105.60 Billion
≈ $71.57 Million
+18.83%
2019-12-31 ₩88.87 Billion
≈ $60.22 Million
+38.91%
2018-12-31 ₩63.97 Billion
≈ $43.35 Million
+5.67%
2017-12-31 ₩60.54 Billion
≈ $41.03 Million
-4.81%
2016-12-31 ₩63.61 Billion
≈ $43.10 Million
-12.40%
2015-12-31 ₩72.61 Billion
≈ $49.21 Million
+39.37%
2014-12-31 ₩52.10 Billion
≈ $35.31 Million
--

About Green Cross Medical Science Corporation

KQ:142280 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$50.61 Million
₩74.68 Billion KRW
Market Cap Rank
#21904 Global
#1324 in Korea
Share Price
₩3435.00
Change (1 day)
-4.18%
52-Week Range
₩3255.00 - ₩6230.00
All Time High
₩19450.00
About

GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CER… Read more